6
Oct
2026

GC Biopharma Corp.

Exhibitor at CPHI Milan 2026 stand 10K1, Contract Manufacturing & Services
About Us

GC Biopharma is a leading global biopharmaceutical company dedicated to improving lives through innovative solutions. With over 55 years of experience, we specialize in developing and manufacturing plasma derivatives, vaccines, and therapies for rare diseases, alongside offering comprehensive CMO services. 

#GreenCross #Plasma Derivatives #Vaccines #Rare Diseases #Cutting-edge Technology #Global Compliance

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2022
  • Certificates:
    3
  • Employees:
    5000+
Company types
Biopharmaceutical company
CMO/CDMO
Primary activities
Biopharmaceutical
Contract Manufacturer
View company profile
Contact info
  • +82 10 8239 3629
  • 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, 16924, Gyeonggi-do, Korea, Republic Of
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 10K1, Contract Manufacturing & Services

Products Featured at CPHI Milan 2026

  • Biologic drug product CMO services - Fill and Finish

    Product Biologic drug product CMO services - Fill and Finish

    GC Biopharma is one of the top-tier biopharmaceutical companies in South Korea with over 55 years of history and advanced technology. GC Biopharma provides premium Fill & Finish service to clinical and commercial customers for vaccines, recombinant and biosimilar pharmaceutical products. We have state-of-t...
  • Barycela

    Product Barycela

    "World’s 1st Antibiotic-free varicella vaccine" • WHO PQ vaccine  • Improved stability with automatic and aseptic process • Over the past 30 years, + 30 M doses provided • Exported more than 30 countries
    • Generic name: Varicella Vaccine • Indication: For prophylaxis against varicella • ...
  • GC Flu

    Product GC Flu

    "Top 5 global flu vaccine manufacturer" • WHO PQ vaccine • Largest flu vaccine supplier to PAHO & Unicef
    • + 300 M doses supplied worldwide • Generic name: Seasonal Influenza vaccine • Indication: For prophylaxis against influenza • Presentation: 0.5 mL(PFS) 0.25 mL(PFS) 0.5 mL (vial...
  • I.V-Globulin SN 5% inj.

    Product I.V-Globulin SN 5% inj.

    "A dominant leader of Korea since 1970" • 611 mil liters of IVIG distriubuted worldwide • Distributed in more than 30 countries • Generic Name: Human Normal Immuoglobulin for Intravenous Administration 5% • Presentation: 50 mL, 100 mL, 200 mL • Storage condition: 2~8 ºC • Shelf life: 30 mon...
  • Alyglo

    Product Alyglo

    "FDA Approved IVIG, Successfully launched in 2024"
    • Extra Purification (>99% FXIa Free) with G-XI Technology • Proven Protection from Infection (0.03 Acute Serious Bacterial Infection per patient year)  • Reduced impact on Daily Living  • Generic Name: ...

GC Biopharma Resources (1)

  • [Plasma derivatives] I.V.-Globulin SN inj

    Brochure [Plasma derivatives] I.V.-Globulin SN inj

    ▪Solvent/Detergent treated and Nanofiltered ▪For intravenous use only ▪Plasma from healthy donors  

     ✔ Alyglo : Human Intravenous immunoglobulin 10%
     - U.S. Approval in 2023
     - Successfully launching in 2024

     ✔ I.V.-Globulin SN inj. : Human intravenous Immunoglobulin 5%, 10%
     - A dominant leader of Korea since 1970
     - 611 mil. liters of IVIG distributed worldwide